Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?

Up to 70% of non-small cell lung cancer (NSCLC) patients develop central nervous system (CNS) metastases during the course of their disease, especially those with oncogenic drivers treated with a first-generation tyrosine kinase inhibitor (TKI), because of the relatively poor CNS penetration. CNS me...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoenmaekers, Janna Josephus Anna Oda, Paats, Marthe Sentijna, Dingemans, Anne-Marie Clasina, Hendriks, Lizza Elisabeth Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815343/
https://www.ncbi.nlm.nih.gov/pubmed/33489821
http://dx.doi.org/10.21037/tlcr-20-459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815343/
https://www.ncbi.nlm.nih.gov/pubmed/33489821
http://dx.doi.org/10.21037/tlcr-20-459

Ejemplares similares